Clinical Trial Search

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg

Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…

Primary: Number of Participants Who Complete the Baseline Assessment — 18 Participants

Primary: Withdrawal Symptom Severity on the Marijuana Withdrawal Checklist (MWC) at 28 Days Following Single Dose Administration of Rimonabant or Placebo, or Commencement of…

Primary: Change in Mental Health Symptoms — -0.02; 0.11 score on a scale

Primary: Mean Difference in the Total Number of Errors From Paired Associates Learning (PAL) Module Averaged Over Weeks 1, 2, 3, and 4 — 5.6; 6.2; 5.9 score on a scale — p=0.215

Primary: Change From Baseline in Cannabis Use at 10 Weeks — 268.8; 286.7; 490.3; 216.9 Ratio

Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants

Primary: Change in Cold Pressor Test (CPT) Latency — 21.40; 10.94; 2.07; 15.17 percent change from Day 1 baseline

Primary: Self-report Instruments to Measure Cannabis Use — 26.72; 5.256 Inhalations of Cannabis Per Day

Primary: Cannabis Withdrawal Symptoms During Active Treatment — 2.23; 3.94; 2.59; 4.07 score on a scale

Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions

Primary: Alpha Learning Rate — .62; .43; .55; .21 Alpha Coefficient

Primary: Percentage of Participants With Cannabis Abstinence or Significant Reduction in Cannabis Use — 7 Participants

Primary: Cannabis Use — 55.89; 63.10 Percentage of use days

Primary: fMRI Connectivity of Regions of Interest (ROI) Within the Brain Reward Circuitry (BRC). — .40; .33 Z score

Primary: Maximum Tolerated Dose of Quetiapine — 197 milligrams

Primary: Continuous Abstinence Via Progressive Declines in Urine THCCOOH — NA ng/mL

Primary: Cannabis Approach Bias — -8.43; 4.05; 5.43; -1.36 seconds

Primary: Marijuana Abstinence — 0; 2 Participants

Primary: Change in Marijuana Withdrawal Checklist (MWC) — 6.04; 11 score on a scale

Primary: Time Line Follow Back (TLFB) for Cannabis Use — 1.921; 1.768; 1.201; 1.066 times/day of self-reported cannabis use

Primary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed

Primary: Tolerability — 0; 0; 0 Participants

Primary: Marijuana Use, Daily Dollar Averaged Over 7 Days During Each of 12 Weeks of Study — 14.00; 7.00; 10.00; 8.00 dollars

Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale

Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale

Primary: App Feasibility — 122 Participants

Primary: Global Cognitive Ability (GCA) — -1.99; -0.82 Standard score (Z-score) — p=0.005

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 12 — -966.00; -532.81 ng/ml — p=.029